Janus Henderson Group PLC Has $11.31 Million Stock Holdings in Incyte Co. (NASDAQ:INCY)

Janus Henderson Group PLC lessened its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 6.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 171,129 shares of the biopharmaceutical company's stock after selling 11,552 shares during the period. Janus Henderson Group PLC owned 0.09% of Incyte worth $11,311,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. MFA Wealth Advisors LLC acquired a new position in shares of Incyte during the second quarter valued at $26,000. Brooklyn Investment Group acquired a new position in Incyte during the 3rd quarter valued at about $30,000. Innealta Capital LLC bought a new position in Incyte in the 2nd quarter worth about $32,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Incyte in the third quarter valued at approximately $33,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Incyte in the second quarter valued at approximately $36,000. Institutional investors and hedge funds own 96.97% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Cantor Fitzgerald reissued a "neutral" rating on shares of Incyte in a report on Tuesday, November 19th. Oppenheimer boosted their price target on Incyte from $81.00 to $82.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Citigroup raised their price target on Incyte from $92.00 to $97.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. StockNews.com upgraded shares of Incyte from a "buy" rating to a "strong-buy" rating in a research note on Thursday, November 28th. Finally, JMP Securities reiterated a "market perform" rating on shares of Incyte in a research report on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $77.16.

Insider Activity

In other Incyte news, EVP Jonathan Elliott Dickinson sold 8,450 shares of Incyte stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.36, for a total transaction of $526,942.00. Following the completion of the sale, the executive vice president now owns 36,390 shares of the company's stock, valued at $2,269,280.40. This trade represents a 18.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Vijay K. Iyengar sold 6,043 shares of the company's stock in a transaction on Friday, November 29th. The stock was sold at an average price of $75.38, for a total transaction of $455,521.34. Following the completion of the transaction, the executive vice president now directly owns 30,658 shares in the company, valued at $2,311,000.04. This trade represents a 16.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,745 shares of company stock worth $1,311,687. 17.60% of the stock is owned by corporate insiders.

Incyte Trading Down 5.0 %

INCY stock traded down $3.81 during mid-day trading on Monday, reaching $72.11. 1,758,125 shares of the stock traded hands, compared to its average volume of 2,347,125. The stock's fifty day moving average is $71.86 and its 200-day moving average is $65.92. The company has a market cap of $13.89 billion, a P/E ratio of 515.07, a P/E/G ratio of 8.75 and a beta of 0.69. The company has a current ratio of 1.87, a quick ratio of 1.82 and a debt-to-equity ratio of 0.01. Incyte Co. has a 52-week low of $50.35 and a 52-week high of $83.95.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.07 EPS for the quarter, missing analysts' consensus estimates of $1.19 by ($0.12). Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the business posted $0.91 EPS. The company's revenue for the quarter was up 23.8% on a year-over-year basis. As a group, sell-side analysts expect that Incyte Co. will post 0.4 earnings per share for the current year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.